UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
EDEN PRAIRIE, Minn., March 07, 2018 -- CHF Solutions (Nasdaq:CHFS), today announces that it will be exhibiting at the 67th Annual Scientific Sessions of the American College of Cardiology (ACC) from March 10-12 in Orlando, Florida.
The company will be exhibiting its Aquadex FlexFlow System and can be found on the exhibition floor at the Orange County Convention Center, Booth #1505 during the conference.
“Attending the ACC Conference is an important venue to demonstrate the clinical and economic value of our Aquadex FlexFlow System. We look forward to connecting with the Cardiology community at the ACC Conference and further educating the attendees on the value of our Ultrafiltration System,” said Jim Breidenstein, chief commercial officer of CHF Solutions.
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
CONTACTS:
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
[email protected]
-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
[email protected]
www.coreir.com
MEDIA
Jules Abraham
JQA Partners, Inc.
917-885-7378
[email protected]
